CLB 3000 Hepatitis B vaccine - ClearB Therapeutics
Alternative Names: CLB-3000; CLB-405+CLB-505 Alhydrogel; Hepatitis B vaccine - ClearB TherapeuticsLatest Information Update: 19 Oct 2023
At a glance
- Originator ClearB Therapeutics
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Hepatitis B
Most Recent Events
- 12 Oct 2023 Phase-I clinical trials in Hepatitis B in Australia (Parenteral) (ACTRN1263000841673)
- 21 Jun 2023 Pharmacodynamics data from a preclinical study in Hepatitis B presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)
- 04 Nov 2022 Adverse events data from a preclinical study in Hepatitis B presented at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2022)